CALR突变骨髓增殖性肿瘤对TYK2信号的选择性依赖
本研究探讨TYK2在CALR突变与JAK2V617F突变骨髓增殖性肿瘤(MPN)中的差异作用。发现CALRdel52/ins5及MPLW515K表达细胞存在TYK2组成性磷酸化,而JAK2V617F细胞无此现象。TYK2抑制剂deucravacitinib选择性降低CALR突变细胞活力及STAT3/5磷酸化,与fedratinib联用效果增强。原代样本中deucravacitinib抑制ET和PMF集落生长,选择性降低CALR突变等位基因负荷。
要点
- CALR突变MPN存在TYK2组成性磷酸化,JAK2V617F MPN不依赖TYK2。
- deucravacitinib选择性抑制CALR突变细胞活力,与fedratinib联用增效。
- deucravacitinib抑制ET/PMF集落生长并降低CALR突变等位基因负荷。
核心结论
- TYK2是CALR突变MPN的选择性脆弱点,支持TYK2/JAK2联合抑制策略以克服JAK2依赖耐药。
研究设计与样本
- 实验研究,使用CALRdel52/ins5、MPLW515K和JAK2V617F表达细胞、原代MPN样本及患者iPSC来源CD34+祖细胞。
主要发现
- CALRdel52/ins5和MPLW515K表达细胞存在TYK2组成性磷酸化,JAK2V617F细胞无此现象。
- deucravacitinib降低CALRdel52/ins5和MPLW515K突变细胞活力及STAT3/5磷酸化,对JAK2V617F突变细胞无效。
- deucravacitinib与fedratinib联用对CALR突变细胞效果增强。
- 原代样本中deucravacitinib显著抑制ET和PMF集落生长,不抑制PV,选择性降低CALR突变等位基因负荷。
- CALR突变患者iPSC来源CD34+祖细胞TYK2磷酸化增加,对TYK2抑制更敏感。
临床怎么用
- deucravacitinib可考虑用于CALR突变ET/PMF,尤其与JAK2抑制剂联用以克服耐药。
局限性
- 研究未报告样本量、P值等统计细节,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPN) are driven by the oncoproteins JAK2V617F, mutant calreticulin (CALR), and mutant thrombopoietin receptor (TPOR; MPL), all of which activate JAK/STAT signaling. While JAK2 signaling is engaged in all MPNs, TYK2 is dispensable for JAK2V617F-driven disease. Here, we hypothesized a distinct role for TYK2 in CALR-mutant driven MPN. We found constitutive TYK2 phosphorylation in CALRdel52/ins5- and MPLW515K- but not JAK2V617F-expressing cells. Structural modeling predicted similar TPOR-binding affinities for JAK2 and TYK2, while micropatterning experiments demonstrated that both JAK2WT and JAK2V617F displace TYK2 from the receptor. The TYK2 inhibitor deucravacitinib reduced viability and STAT3/5 phosphorylation in CALRdel52/ins5- and MPLW515K- but not JAK2V617F-mutant cells, with enhanced efficacy when combined with the JAK2-selective inhibitor fedratinib. Cellular response correlated with JAK2 protein abundance, as CALRins5 JAK2high clones outcompeted JAK2low clones upon TYK2 inhibition. In primary samples, deucravacitinib significantly suppressed colony growth in ET and PMF but not PV, and selectively reduced CALR- but not JAK2V617F-mutant allele burden. Similarly, CALR-mutant patient-specific iPSC-derived CD34+ progenitors showed increased TYK2 phosphorylation and were more sensitive to TYK2 inhibition than their JAK2V617F counterparts. These findings identify TYK2 as a selective vulnerability in CALR-mutant MPN and support combined TYK2/JAK2 inhibition strategies to overcome JAK2-dependent resistance.
引用
- Kalmer M, Wirths C, Lemanzyk R, et al. Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling. Leukemia. 2026. PMID: 42786200. doi:10.1038/s41375-026-03139-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。